Kihealth is commercializing a laboratory-developed blood test that measures biomarkers of pancreatic beta cell apoptosis, enabling the earliest detection of insulin resistance and chronic metabolic diseases. The assay, created with leading academic researchers, offers clinicians unprecedented insight into beta cell viability and can stratify patients, monitor therapeutic response, and improve enrollment for diabetes and obesity trials. By unlocking a largely untapped diagnostics market estimated at over $2 billion and facing virtually no direct competition, the company positions itself as a key enabler of preventive medicine. Kihealth’s platform is designed to expand into additional minimally invasive diagnostics that uncover hidden disease processes earlier and with greater precision. The test has already won the 2025 American Diabetes Association Innovation of the Year Award, underscoring its clinical relevance. Proceeds from the recent financing will fund the commercial rollout of the first assay and advance a broader diagnostic pipeline. The oversubscribed seed round also signals strong investor confidence in Kihealth’s technology and market opportunity.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2025